Menu Search
Equities

Bachem Holding AG

BANB:SWX

Bachem Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)69.90
  • Today's Change0.10 / 0.14%
  • Shares traded2.12k
  • 1 Year change-1.13%
  • Beta1.1659
Data delayed at least 15 minutes, as of Nov 22 2024 08:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform3
Hold3
Sell2
Strong Sell0

Share price forecast in CHF

The 8 analysts offering 12 month price targets for BACHEM HOLDING AG have a median target of 80.50, with a high estimate of 100.00 and a low estimate of 52.00. The median estimate represents a 15.33% increase from the last price of 69.80.
High43.3%100.00
Med15.3%80.50
Low-25.5%52.00

Dividends in CHF

In 2023, Bachem Holding AG reported a dividend of 0.80 CHF, which represents a 6.67% increase over last year. The 5 analysts covering the company expect dividends of 0.86 CHF for the upcoming fiscal year, an increase of 7.25%.
Div growth (TTM)6.67%
More ▼

Earnings history & estimates in CHF

BACHEM HOLDING AG reported annual 2023 earnings of 1.50 per share on Mar 07, 2024.
Average growth rate+20.46%
More ▼

Revenue history & estimates in CHF

Bachem Holding AG had revenues for the full year 2023 of 577.32m. This was 8.57% above the prior year's results.
Average growth rate+16.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.